Abstract
Aim and Objective: To assess the relationship between serum folate and schizophrenia (SZ) risk in the Chinese Han adult population in different papers, a systematic review and metaanalysis were conducted.
Materials and Methods: We searched for this meta-analysis on three English databases (PubMed, Embase, and Web of science) and four Chinese databases (CNKI, SinoMed, Wanfang, and CQVIP) on March 27, 2021. Inclusion criteria: studies provided folate levels in serum of cases and controls as mean and standard deviation. Exclusion criteria: subjects were not Chinese Han adult population. The Newcastle-Ottawa Scale score was used to assess the risk of bias in the included studies. Standard mean difference (SMD) was used to measure the difference between SZ patients and healthy controls. Subgroup analyses by measurement time, duration, and age were performed, respectively.
Results: This meta-analysis included 19 publications involving 1571 SZ cases and 1283 healthy controls. In total studies, the pooled result showed that SZ patients had decreased serum folate levels compared with healthy controls (SMD [95%CI] = -1.37[-1.83,-0.90], PSMD<0.001), and in most of the subgroups, the associations reached decreased significantly; while in the subgroup of drugs use, the association was not reached significantly.
Conclusion: Dose-response analysis and subgroup analyses by gender were not performed due to the lack of data. Folate deficiency is associated with the patients, and antipsychotic drugs might have positive effects on improving serum folate levels in Chinese Han adult SZ.
Keywords: Chinese Han adult population, folate, meta-analysis, schizophrenia, serum, folic acid.
Graphical Abstract
[1]
Su, L.; Cai, Y.; Wang, L.; Shi, S. Various effects of antipsychotics on P50 sensory gating in Chinese schizophrenia patients: A meta-analysis. Psychiatr. Danub., 2012, 24(1), 44-50.
[PMID: 22447085]
[PMID: 22447085]
[2]
Howes, O.D.; Murray, R.M. Schizophrenia: An integrated sociodevelopmental-cognitive model. Lancet, 2014, 383(9929), 1677-1687.
[http://dx.doi.org/10.1016/S0140-6736(13)62036-X] [PMID: 24315522]
[http://dx.doi.org/10.1016/S0140-6736(13)62036-X] [PMID: 24315522]
[3]
Brown, A.S. The environment and susceptibility to schizophrenia. Prog. Neurobiol., 2011, 93(1), 23-58.
[http://dx.doi.org/10.1016/j.pneurobio.2010.09.003] [PMID: 20955757]
[http://dx.doi.org/10.1016/j.pneurobio.2010.09.003] [PMID: 20955757]
[4]
Wu, H.J.; Li, R.X.; Zeng, C.J.; Wu, X.X. Folate concentration variation in schizophrenia. Shihezi Tech, 1995, 5, 48.
[5]
Duan, X.X.; Chen, Y.; Shen, D.H.; Yang, Y.C.; Ma, J.; He, R.F. Correlation study between serum homocysteine,folic acid levels and PANSS score in children and adolescents patients with schizophrenia. Xiandai Jianyan Yixue Zazhi, 2019, 34(1), 104-106.
[6]
Zhang, W.Y.; Lin, H.; Zhao, H.Q.; Huang, H.; Xuan, C.M. A study of the serum level of homocysteine in obesity patients induced by antipsychotics. J. Clin. Psychol. Med., 2007, 17(2), 79-81.
[7]
Zhang, W.Y.; Lin, H.; Zhao, H.Q.; Huang, H.; Xuan, C.M.; Ma, J.F. Cognitive function in the first-episode schizophrenics and its association with serum level of homocysteine. Chin. J. Nerv. Ment. Dis., 2007, 33(11), 652-656.
[8]
Qian, Z.K.; Jiang, C.X.; Du, X.D. Relationship between plasma homocysteine,serum folate levels and first-episode schizophrenic patients. J. Med. Sci., 2009, 29(6), 1140-1142.
[9]
Liang, J.; Dong, Y.X.; Meng, X.J. Effects of olanzapine on levels of serum folic acid, homocysteine and brain-derived neurotrophic factor in first-episode schizophrenic patients. J. Clin. Psychiatry, 2016, 26(4), 266-267.
[10]
Zhang, Y.; Chen, M.J.; Xu, F.K.; Shen, H.; Qian, Z.S. Correlation between high homocysteine levels and cognitive dysfunction in first-episode schizophrenia. J. Psychiatry, 2016, 29(5), 342-345.
[11]
Hao, K.R.; Ji, J.W.; Zheng, Y. Changing characteristics of plasm homocysteine and serum folic acid levels in first-episode schizophrenia. Chin. J. Clinical Rational Drug Use, 2017, 10(28), 112-113.
[12]
Wells, G.; Shea, B.; Oconnell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site, 2014.
[13]
Higgins, J.P.T.; Green, S. Cochrane handbook for systematic reviews of interventions version 5.1. 0; John Wiley & Sons, 2011. Available from: www.cochrane-handbook.org [updated March 2011].
[14]
Song, X.; Fan, X.; Li, X.; Kennedy, D.; Pang, L.; Quan, M.; Chen, X.; Gao, J.; Zhang, W.; Zhang, J.; Lv, L. Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophr. Res., 2014, 159(1), 51-55.
[http://dx.doi.org/10.1016/j.schres.2014.07.033] [PMID: 25128453]
[http://dx.doi.org/10.1016/j.schres.2014.07.033] [PMID: 25128453]
[15]
Zhu, Z.X.; Xiong, P.; Jia, M.; Wan, J.; Zeng, Y.; Xu, M.J. Serum level of homocysteine in the first-episode schizophrenics and its correlation with P_300. Chin. J. Nerv. Ment. Dis., 2010, 36(6), 355-358.
[16]
Zhang, G.F.; Ren, C.X.; Qi, S.G.; Zhang, Y.B.; Lu, Z.X.; Lv, Z.L. Study of plasma hydrogen sulfide, homocysteine,folate and vitaminB6 in Schizophrenia patients. J. Clin. Psychiatry, 2011, 21(1), 24-26.
[17]
Chen, X.; Zhu, Q.; Zhang, W.; Li, X.; Hao, Y.; Li, Y.; Lü, L.; Song, X. Correlation between serum levels of homocysteine and folate and cognitive dysfunction in first-episode schizophrenics. Zhonghua Yi Xue Za Zhi, 2014, 94(13), 990-993.
[PMID: 24851685]
[PMID: 24851685]
[18]
Sun, Y.Y.; Zhu, Y.H.; Sun, J.J.; Pan, S.M.; Ma, W. Correlation of attention and executive functioning to serum homocysteine level in patients with schizophrenia. Chin. Ment. Health J., 2014, 28(11), 835-839.
[19]
Cui, M.; Kang, X.Y.; Zhuang, R.; Jiang, D.; Zeng, B.T. Correlation between serum folate, homocysteine and P300 in patients with first-episode schizophrenia J. Neuroscience and Mental Health, 2015, 15(3), 225-227.
[20]
Xu, X.J. The corelation between serum homocysteine and attentional and executive functions in schizophrenia patients. Guide of China Med., 2018, 16(17), 79-80.
[21]
Zhang, P.F. [Study on the relationship between oxidative stress, mental symptoms and cognitive function in patients with firstepisode untreated schizophrenia]., Zhengzhou, Henan, China: Zhengzhou University, 2019.
[22]
Feng, L.G. shao, C.Q.; Qi, P.P.; Tao, Y.H.; Hu, J. Relationships between homocysteine, folate, vitamin B12 and schizophrenia. Chin. J. Nerv. Ment. Dis., 2009, 35(1), 40-41.
[23]
Hei, G.; Pang, L.; Chen, X.; Zhang, W.; Zhu, Q.; Lü, L.; Song, X. Association of serum folic acid and homocysteine levels and 5, 10-methylenetetrahydrofolate reductase gene polymorphism with schizophrenia. Zhonghua Yi Xue Za Zhi, 2014, 94(37), 2897-2901.
[PMID: 25549641]
[PMID: 25549641]
[24]
Wang, Q.; Wu, Y.P. The study on relationship between serum folate, homocysteine levels and cognitive function in first-episode schizophrenic patients Annual conference of digital Traditional Chinese Medicine branch association of international digital medical association and the 2nd digital Traditional Chinese Medicine academic exchange meeting, 2017, p. 99.
[25]
Fang, Z.H.; Liu, L.N.; Sheng, X.; Zhou, J. Effects of olanzapine and parioperazone on serum folic acid, homocysteine and brain-derived neurotrophic factor in patients with first-onset schizophrenia. J. Intl. Psychiatry, 2019, 46(1), 71-74.
[26]
Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109), 629-634.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[27]
Deng, J.; Mao, X.X.; Li, Z.; Lu, X.Y. The relationship between cognitive ability and the level of serum homocysteine in patients with first-episode schizophrenia. J. Intl. Psychiatry, 2018, 45(1), 36-38.
[28]
Li, G.X.; Tang, X.W.; Zhu, Q.; Xia, X.L.; Ye, F.; Zhao, X.Y. Association of serum interleukin-6, -10, folic acid and cognitive function in male chronic schizophrenic patients with mainly negative symptoms. J. Clin. Psychiatry, 2019, 29(1), 35-38.
[29]
Zhilyaeva, T.V.; Sergeeva, A.V.; Blagonravova, A.S.; Mazo, G.E.; Kibitov, A.O. One-Carbon metabolism disorders in schizophrenia: genetic and therapeutic aspects. Neurochem. J., 2019, 13(2), 113-120.
[http://dx.doi.org/10.1134/S1819712419020156]
[http://dx.doi.org/10.1134/S1819712419020156]
[30]
Ozsoy, S.; Izgi, H.B.; Esel, E.; Turan, T.; Basturk, M.; Sofuoglu, S. The effects of pharmachotherapy on serum folic acid and vitamin B12 levels in patients with schizophrenia, bipolar disorder and major depressive disorder. Klinik Psikofarmakoloji Bulteni, 2009, 19(2), 128-134.
[31]
Bouaziz, N.; Ayedi, I.; Sidhom, O.; Kallel, A.; Rafrafi, R.; Jomaa, R.; Melki, W.; Feki, M.; Kaabechi, N.; El Hechmi, Z. Plasma homocysteine in schizophrenia: Determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res., 2010, 179(1), 24-29.
[http://dx.doi.org/10.1016/j.psychres.2010.04.008] [PMID: 20471108]
[http://dx.doi.org/10.1016/j.psychres.2010.04.008] [PMID: 20471108]
[32]
Trujillo, F.J.; Raya, J.M.; Monzon, J.; Rodriguez-Martos, T.; Salinas, M.; Martin-Santos, T.; Sangines, M.; Henry, M.; Jimenez-Sosa, A.; Gracia, R. Serum folate, vitamin B12, and homocysteine in acute patients with schizophrenia, depression, or bipolar disorder. Eur. Neuropsychopharmacol., 2009, 19(Suppl. 3), S344-S345.
[http://dx.doi.org/10.1016/S0924-977X(09)70521-8]
[http://dx.doi.org/10.1016/S0924-977X(09)70521-8]
[33]
Misiak, B.; Frydecka, D.; Slezak, R.; Piotrowski, P.; Kiejna, A. Elevated homocysteine level in first-episode schizophrenia patients-the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab. Brain Dis., 2014, 29(3), 661-670.
[http://dx.doi.org/10.1007/s11011-014-9534-3] [PMID: 24682777]
[http://dx.doi.org/10.1007/s11011-014-9534-3] [PMID: 24682777]
[34]
Brown, H.E.; Roffman, J.L. Vitamin supplementation in the treatment of schizophrenia. CNS Drugs, 2014, 28(7), 611-622.
[http://dx.doi.org/10.1007/s40263-014-0172-4] [PMID: 24846474]
[http://dx.doi.org/10.1007/s40263-014-0172-4] [PMID: 24846474]
[35]
Muntjewerff, J.W.; Kahn, R.S.; Blom, H.J.; den Heijer, M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: A meta-analysis. Mol. Psychiatry, 2006, 11(2), 143-149.
[http://dx.doi.org/10.1038/sj.mp.4001746] [PMID: 16172608]
[http://dx.doi.org/10.1038/sj.mp.4001746] [PMID: 16172608]
[36]
Nishi, A.; Numata, S.; Tajima, A.; Kinoshita, M.; Kikuchi, K.; Shimodera, S.; Tomotake, M.; Ohi, K.; Hashimoto, R.; Imoto, I.; Takeda, M.; Ohmori, T. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr. Bull., 2014, 40(5), 1154-1163.
[http://dx.doi.org/10.1093/schbul/sbt154] [PMID: 24535549]
[http://dx.doi.org/10.1093/schbul/sbt154] [PMID: 24535549]
[37]
Gayer-Anderson, C.; Jongsma, H.E.; Di Forti, M.; Quattrone, D.; Velthorst, E.; de Haan, L.; Selten, J.P.; Szöke, A.; Llorca, P.M.; Tortelli, A.; Arango, C.; Bobes, J.; Bernardo, M.; Sanjuán, J.; Santos, J.L.; Arrojo, M.; Parellada, M.; Tarricone, I.; Berardi, D.; Ruggeri, M.; Lasalvia, A.; Ferraro, L.; La Cascia, C.; La Barbera, D.; Menezes, P.R.; Del-Ben, C.M.; Rutten, B.P.; van Os, J.; Jones, P.B.; Murray, R.M.; Kirkbride, J.B.; Morgan, C. The EUropean network of national schizophrenia networks studying gene-environment interactions (EU-GEI): Incidence and first-episode case-control programme. Soc. Psychiatry Psychiatr. Epidemiol., 2020, 55(5), 645-657.
[http://dx.doi.org/10.1007/s00127-020-01831-x] [PMID: 31974809]
[http://dx.doi.org/10.1007/s00127-020-01831-x] [PMID: 31974809]
[38]
Lien, W.C.; Wang, W.M.; Wang, H.D.; Lin, F.H.; Yao, F.Z. Environmental barriers and functional outcomes in patients with schizophrenia in Taiwan: The capacity-performance discrepancy. Int. J. Environ. Res. Public Health, 2021, 19(1), 315.
[http://dx.doi.org/10.3390/ijerph19010315] [PMID: 35010575]
[http://dx.doi.org/10.3390/ijerph19010315] [PMID: 35010575]
[39]
Rouse, B.; Chaimani, A.; Li, T. Network meta-analysis: An introduction for clinicians. Intern. Emerg. Med., 2017, 12(1), 103-111.
[http://dx.doi.org/10.1007/s11739-016-1583-7] [PMID: 27913917]
[http://dx.doi.org/10.1007/s11739-016-1583-7] [PMID: 27913917]
[40]
Tomioka, Y.; Kinoshita, M.; Umehara, H.; Nakayama, T.; Watanabe, S.Y.; Nakataki, M.; Numata, S.; Ohmori, T. Association between serum folate levels and schizophrenia based on sex. Psychiatry Clin. Neurosci., 2020, 74(9), 466-471.
[http://dx.doi.org/10.1111/pcn.13074] [PMID: 32445495]
[http://dx.doi.org/10.1111/pcn.13074] [PMID: 32445495]
[41]
Burghardt, K.J.; Pilsner, J.R.; Bly, M.J.; Ellingrod, V.L. DNA methylation in schizophrenia subjects: Gender and MTHFR 677C/T genotype differences. Epigenomics, 2012, 4(3), 261-268.
[http://dx.doi.org/10.2217/epi.12.25] [PMID: 22690662]
[http://dx.doi.org/10.2217/epi.12.25] [PMID: 22690662]
Related Journals
Current Computer-Aided Drug Design
Article Metrics
1